<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002091" GROUP_ID="STROKE" ID="728299102812592878" MERGED_FROM="" MODIFIED="2009-05-06 15:07:38 +0200" MODIFIED_BY="Hazel Fraser" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.0.20" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2009-05-06 15:07:38 +0200" MODIFIED_BY="Hazel Fraser">
<TITLE>Interventions in the management of serum lipids for preventing stroke recurrence</TITLE>
<CONTACT MODIFIED="2009-05-06 15:07:38 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16505" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bradley</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Manktelow</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>bm18@leicester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Health Sciences</DEPARTMENT><ORGANISATION>University of Leicester</ORGANISATION><ADDRESS_1>22-28 Princess Road West</ADDRESS_1><CITY>Leicester</CITY><ZIP>LE1 6TP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 116 2525496</PHONE_1><FAX_1>+44 116 2523272</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2009-05-06 15:07:38 +0200" MODIFIED_BY="Hazel Fraser"><PERSON ID="16505" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Bradley</FIRST_NAME><MIDDLE_INITIALS>N</MIDDLE_INITIALS><LAST_NAME>Manktelow</LAST_NAME><POSITION>Statistician</POSITION><EMAIL_1>bm18@leicester.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Department of Health Sciences</DEPARTMENT><ORGANISATION>University of Leicester</ORGANISATION><ADDRESS_1>22-28 Princess Road West</ADDRESS_1><CITY>Leicester</CITY><ZIP>LE1 6TP</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 116 2525496</PHONE_1><FAX_1>+44 116 2523272</FAX_1></ADDRESS></PERSON><PERSON ID="9234" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>John</FIRST_NAME><MIDDLE_INITIALS>F</MIDDLE_INITIALS><LAST_NAME>Potter</LAST_NAME><EMAIL_1>john.potter@uea.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Medicine, Health Policy and Practice</DEPARTMENT><ORGANISATION>University of East Anglia</ORGANISATION><CITY>Norwich</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2009-04-08 13:40:40 +0100" MODIFIED_BY="Hazel Fraser">
<UP_TO_DATE>
<DATE DAY="17" MONTH="12" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2009-05-06 14:02:53 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-05-06 14:02:39 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="17" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>With the addition of three included studies (<LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK>; <LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>; <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>), there is now evidence of a reduction in subsequent serious vascular events from statin therapy in patients with a history of ischaemic stroke or transient ischaemic attack.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-05-06 14:02:53 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="17" MONTH="12" YEAR="2008"/>
<DESCRIPTION>
<P>The literature searches have been updated to December 2008 and three new trials have been included, giving a total of eight included studies involving approximately 10,000 participants.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-09-03 12:34:55 +0100" MODIFIED_BY="Hazel Fraser">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-09-03 12:34:55 +0100" MODIFIED_BY="Hazel Fraser">
<DATE DAY="27" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-05-06 09:16:04 +0100" MODIFIED_BY="Hazel Fraser">
<SUMMARY MODIFIED="2009-04-17 16:48:44 +0100" MODIFIED_BY="Hazel Fraser">
<TITLE MODIFIED="2008-09-03 12:39:18 +0100" MODIFIED_BY="Hazel Fraser">Interventions in the management of serum lipids for preventing stroke recurrence</TITLE>
<SUMMARY_BODY MODIFIED="2009-04-17 16:48:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is evidence of a reduction in subsequent serious vascular events from statin therapy in patients with a history of ischaemic stroke or transient ischaemic attack (TIA). Studies have shown that interventions for reducing either total serum cholesterol or low density lipoprotein cholesterol levels reduce the risk of coronary heart disease (CHD) and stroke events in people with a history of CHD. However, for stroke patients the relation between the level of serum cholesterol and cholesterol subfractions with the risk of future stroke or cardiovascular events is unclear. This review, which includes eight studies involving approximately 10,000 participants, shows statin therapy, but not other lipid-lowering measures, reduces the risk of subsequent major vascular events and a marginal benefit in decreasing stroke events, but not all-cause mortality in those with a history of ischaemic cerebrovascular disease.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-05-06 09:14:45 +0100" MODIFIED_BY="Hazel Fraser">
<ABS_BACKGROUND MODIFIED="2009-04-17 15:28:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>Studies have shown that interventions which reduce total and low-density lipoprotein cholesterol levels also reduce coronary heart disease (CHD) and stroke events in those with a history of CHD. However, it is uncertain whether treatment to alter cholesterol levels can prevent recurrence of either stroke or subsequent cardiovascular events and whether differences in outcomes exist between classes of lipid-lowering therapy. This is an update of a Cochrane review first published in 2002.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-04-08 13:44:34 +0100" MODIFIED_BY="Hazel Fraser">
<P>To investigate the effect of altering serum lipids pharmacologically for preventing subsequent cardiovascular disease and stroke recurrence in patients with a history of stroke.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-04-17 15:22:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>We searched the Cochrane Stroke Group Trials Register (last searched December 2008), the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library</I> Issue 3, 2008), MEDLINE (1966 to December 2008) and EMBASE (1980 to December 2008). We contacted pharmaceutical companies known to produce a lipid-lowering agent for information on relevant publications or unpublished work.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-04-08 13:49:13 +0100" MODIFIED_BY="Hazel Fraser">
<P>Unconfounded randomised trials of participants aged 18 years and over with a history of stroke or transient ischaemic attack (TIA).</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-04-08 13:45:49 +0100" MODIFIED_BY="Hazel Fraser">
<P>Two review authors independently selected trials, assessed quality and extracted data. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-04-17 15:23:55 +0100" MODIFIED_BY="Hazel Fraser">
<P>We included eight studies involving approximately 10,000 participants. The active interventions were pravastatin, atorvastatin, simvastatin, clofibrate, and conjugated oestrogen. Fixed-effect analysis showed no overall effect on stroke recurrence but statin therapy alone had a marginal benefit in reducing subsequent cerebrovascular events in those with a previous history of stroke or TIA (odds ratio (OR) 0.88, 95% confidence interval (CI) 0.77 to 1.00). There was no evidence that such intervention reduced all-cause mortality or sudden death (OR 1.00, 95% CI 0.83 to 1.20). Three statin trials showed a reduction in subsequent serious vascular events (OR 0.74, 95% CI 0.67 to 0.82).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-05-06 09:14:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is evidence that statin therapy in patients with a history of ischaemic stroke or TIA significantly reduces subsequent major coronary events but only marginally reduces the risk of stroke recurrence. There is no clear evidence of beneficial effect from statins in those with previous haemorrhagic stroke and it is unclear whether statins should be started immediately post stroke or later. In view of this and the evidence of the benefit of statin therapy in those with a history of CHD, patients with ischaemic stroke or TIA, with or without a history of established CHD, should receive statins.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-05-06 09:16:03 +0100" MODIFIED_BY="Hazel Fraser">
<BACKGROUND MODIFIED="2009-05-06 09:14:57 +0100" MODIFIED_BY="Hazel Fraser">
<P>A close association between serum lipid levels and the incidence of coronary heart disease (CHD) has been well proven in middle-aged and elderly people. The UK Joint Working Party called the evidence that patients with established CHD benefit from cholesterol reduction "exceptionally strong" and recommended that all patients with established coronary artery disease should have their serum cholesterol reduced to at least below 5.0 mmol/l (<LINK REF="REF-Wood-1998" TYPE="REFERENCE">Wood 1998</LINK>). The British Hypertension Society (<LINK REF="REF-Williams-2004" TYPE="REFERENCE">Williams 2004</LINK>) and Joint British Society guidelines on prevention of cardiovascular disease (<LINK REF="REF-JBS2-2005" TYPE="REFERENCE">JBS2 2005</LINK>) make similar recommendations. However, the relation between plasma cholesterol and cholesterol sub-fractions with cerebrovascular disease is much more controversial. Two meta-analyses of observational data on the relation between serum lipid levels and stroke highlight the uncertainty in the relation between serum lipids and stroke recurrence: one of the studies involved 61 observational cohorts of 900,000 individuals (<LINK REF="REF-PSC-2007" TYPE="REFERENCE">PSC 2007</LINK>) and the other 13 cohorts of 125,000 Asian participants (<LINK REF="REF-ESCHD-1998" TYPE="REFERENCE">ESCHD 1998</LINK>). The Prospective Studies Collaborative found no positive association between cholesterol and stroke (including cerebral infarction, cerebral haemorrhage and unclassified stroke) apart from a weak link in those in early middle age (40 to 59 years of age). In the study of Asian populations, no clear relation between cholesterol levels and stroke was found, though there was a trend towards a lower risk of non-haemorrhagic and an increased risk of haemorrhagic stroke with decreasing cholesterol levels.</P>
<P>Direct evidence from randomised trials involving agents that alter serum lipid levels to prevent first-time strokes (i.e. primary stroke prevention) is also lacking (<LINK REF="REF-Atkins-1993" TYPE="REFERENCE">Atkins 1993</LINK>; <LINK REF="REF-Hebert-1995" TYPE="REFERENCE">Hebert 1995</LINK>). However, meta-analyses of the accumulated data do suggest that HMG-CoA reductase inhibitors, i.e. statins, may reduce primary stroke incidence (<LINK REF="REF-Blauw-1997" TYPE="REFERENCE">Blauw 1997</LINK>; <LINK REF="REF-Bucher-1998" TYPE="REFERENCE">Bucher 1998</LINK>; <LINK REF="REF-Byington-2001" TYPE="REFERENCE">Byington 2001</LINK>; <LINK REF="REF-Crouse-1997" TYPE="REFERENCE">Crouse 1997</LINK>; <LINK REF="REF-Di-Mascio-2000" TYPE="REFERENCE">Di Mascio 2000</LINK>; <LINK REF="REF-Hebert-1997" TYPE="REFERENCE">Hebert 1997</LINK>). The Cholesterol Treatment Trialists' Collaboration (<LINK REF="REF-CTT-2005" TYPE="REFERENCE">CTT 2005</LINK>) reported a reduction in non-haemorrhagic stroke incidence with LDL cholesterol reduction but not in haemorrhagic strokes. Other evidence suggests that reducing total serum cholesterol levels may paradoxically increase the risk of a haemorrhagic stroke (<LINK REF="REF-Law-2003" TYPE="REFERENCE">Law 2003</LINK>).</P>
<P>If the relation between serum lipids and primary stroke incidence is unclear, the association between stroke recurrence and serum cholesterol is even more uncertain (<LINK REF="REF-McNaughton-2002" TYPE="REFERENCE">McNaughton 2002</LINK>). There is no consistent evidence available yet as to whether lipid levels post stroke are a risk factor for recurrence and whether treatment to alter levels is of benefit in terms of prevention for either stroke recurrence or any subsequent cardiovascular event. Indeed, there is observational evidence that higher serum cholesterol concentrations in the immediate post-stroke period are associated with increased survival (<LINK REF="REF-Dyker-1997" TYPE="REFERENCE">Dyker 1997</LINK>; <LINK REF="REF-Sandercock-2001" TYPE="REFERENCE">Sandercock 2001</LINK>; <LINK REF="REF-Vauthey-2000" TYPE="REFERENCE">Vauthey 2000</LINK>). A similar confused picture exists between the relation of blood lipids in the non-acute post-stroke period and stroke recurrence. The mainly cohort studies to date have either taken people who have experienced an unspecified cerebrovascular event (<LINK REF="REF-Jorgensen-1997" TYPE="REFERENCE">Jorgensen 1997</LINK>) or included only haemorrhagic strokes (<LINK REF="REF-Neau-1997" TYPE="REFERENCE">Neau 1997</LINK>; <LINK REF="REF-Passero-1995" TYPE="REFERENCE">Passero 1995</LINK>), while a further group considered minor ischaemic events, including transient ischaemic attacks (TIAs), as well as acute ischaemic strokes (<LINK REF="REF-Candelise-1986" TYPE="REFERENCE">Candelise 1986</LINK>; <LINK REF="REF-Eliasziw-1995" TYPE="REFERENCE">Eliasziw 1995</LINK>; <LINK REF="REF-Marshall-1961" TYPE="REFERENCE">Marshall 1961</LINK>; <LINK REF="REF-Moroney-1997" TYPE="REFERENCE">Moroney 1997</LINK>; <LINK REF="REF-Prencipe-1998" TYPE="REFERENCE">Prencipe 1998</LINK>; <LINK REF="REF-Sorensen-1989" TYPE="REFERENCE">Sorensen 1989</LINK>; <LINK REF="REF-van-Latum-1995" TYPE="REFERENCE">van Latum 1995</LINK>). However, there is added confusion in that stroke classification, both initial and subsequent, had not been taken into account and the measures of serum lipid levels differed between reports (i.e. some have used total serum cholesterol, others triglycerides or lipoprotein sub-fraction levels). In addition, some studies have used lipid levels taken in the acute stroke period on which to base the outcome analysis, whereas others have taken measurements made weeks to months after the event. There is evidence that lipid levels in the immediate post-stroke period differ from those taken some weeks after the event, with levels falling in the post-stroke period (<LINK REF="REF-Butterworth-1997" TYPE="REFERENCE">Butterworth 1997</LINK>; <LINK REF="REF-Mendez-1987" TYPE="REFERENCE">Mendez 1987</LINK>).</P>
<P>It is also unclear from observational studies whether total serum cholesterol levels, cholesterol sub-fractions or triglyceride levels are directly related to cerebrovascular disease or whether they are acting as markers for co-morbid conditions, such as CHD, and that it is the latter that is associated with stroke recurrence, not lipid levels per se.</P>
<P>This is an update of a Cochrane review, first published in 2002, which investigates the effects of the treatments that alter serum lipid levels in patients who have had a cerebral infarct, haemorrhage, minor stroke or TIA with stroke recurrence as an outcome measure, taking into account three recently published trials that have specifically looked at the effects of statin therapy in those with a previous history stroke or TIA.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-04-08 13:54:26 +0100" MODIFIED_BY="Hazel Fraser">
<P>To investigate the effects of treatments that alter serum lipid levels in patients who have had a cerebral infarct, haemorrhage, unspecified stroke type, minor stroke or TIA in relation to the outcome measure of stroke recurrence.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-05-06 09:15:12 +0100" MODIFIED_BY="Hazel Fraser">
<SELECTION_CRITERIA MODIFIED="2009-04-17 15:42:42 +0100" MODIFIED_BY="Hazel Fraser">
<CRIT_STUDIES>
<P>Published or unpublished unconfounded randomised trials of interventions in the treatment of serum lipid levels for the prevention of stroke recurrence.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-04-08 13:54:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>Patients over 18 years of age with a history of ischaemic or haemorrhagic stroke, including TIA, who were eligible for randomisation.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-04-08 13:55:56 +0100" MODIFIED_BY="Hazel Fraser">
<P>We investigated all interventions designed to control serum lipid levels. This included drugs (e.g. statins, fibrates, niacin) and diet (e.g. fibre) given at any dose and for any duration. We classified fish oils as either a drug or diet intervention according to the method of administration.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-04-17 15:42:42 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>All ischaemic or haemorrhagic strokes.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Fatal and disabling stroke events.</LI>
<LI>All-cause mortality, including sudden deaths.</LI>
<LI>Serious vascular events (non-fatal stroke, non-fatal myocardial infarction (MI), vascular death).</LI>
<LI>All cardiovascular events (fatal and non-fatal MI, congestive cardiac failure, symptomatic peripheral vascular disease).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-04-17 15:43:17 +0100" MODIFIED_BY="Hazel Fraser">
<P>See the 'Specialized register' section in the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/STROKE/frame.html">Cochrane Stroke Group</A> module.</P>
<P>We searched the Cochrane Stroke Group Trials Register, which was last searched by the Review Group Co-ordinator in December 2008, the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> Issue 3, 2008), MEDLINE (1966 to December 2008) (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and EMBASE (1980 to December 2008). We also contacted the following pharmaceutical companies known to produce a lipid-lowering agent and asked them to provide information on publications or unpublished work relevant to this review.</P>
<UL>
<LI>Bristol Myers Squibb Pharmaceuticals Ltd (pravastatin, cholestyramine);</LI>
<LI>Fournier Pharmaceuticals Ltd (fenofibrate);</LI>
<LI>Merck Sharp &amp; Dohme Ltd (simvastatin);</LI>
<LI>Parke-Davis Research Laboratories (atorvastatin, gemfibrozil);</LI>
<LI>Pharmacia and Upjohn Ltd (acipimox, colestipol);</LI>
<LI>Reckitt and Colman Products Ltd (soluble fibre);</LI>
<LI>Roche Products Ltd (bezafibrate);</LI>
<LI>Sandoz Pharmaceuticals (fluvastatin);</LI>
<LI>Sanofi Winthrop (ciprofibrate);</LI>
<LI>Zeneca Pharmaceuticals (clofibrate).</LI>
</UL>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-05-06 09:15:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>We independently assessed the trials identified. We obtained the full text of all studies where there was no evidence from the abstract that any of the selection criteria were not met by the study. We then confirmed which trials met the selection criteria, with all decisions on the inclusion of a trial being reached by consensus. If we could not reach agreement, we agreed to seek appropriate external advice for a final decision, although this was not necessary in this review. Where necessary, we contacted study authors for clarification. We also planned to contact study authors if information on the primary outcome was missing; however, this was not necessary.</P>
<P>We recorded details of the methodological quality of the included trials. In particular, we extracted details of randomisation, blinding, and participants withdrawn or lost to follow up. We did not use a scoring system for study quality. We included trials with an inadequate method of randomisation (i.e. where allocation could be anticipated or interfered with) because of the possible identification of older trials that were undertaken prior to currently accepted standards of trial design. However, we planned to perform sensitivity analyses by repeating any analysis excluding these studies, but this was not necessary.</P>
<P>We planned to exclude trials of drug interventions without full concealment of treatment allocation from both patients and clinicians, but we did not identify any such trials. Trials of diet interventions should be blind to any person making outcome assessments. We also planned to exclude confounded trials (i.e. trials where an additional active treatment is administered to one of the groups in a non-factorial design), but we did not identify any such trials.</P>
<P>We carried out data extraction independently, and agreed to resolve any disagreements using the procedure outlined above, but we did not disagree on any aspects of data extraction. We estimated the overall treatment effect by the Peto odds ratio (OR) from a fixed-effect model. We carried out all statistical analysis using the Cochrane Review Manager software, Review Manager 5.0 (<LINK REF="REF-RevMan-2008" TYPE="REFERENCE">RevMan 2008</LINK>).</P>
<P>If possible, we planned to perform subgroup analyses to investigate the effect of the following.</P>
<OL>
<LI>Baseline cerebrovascular disease type:</LI>
<OL>
<LI>all strokes and TIAs;</LI>
<LI>all acute strokes;</LI>
<LI>all acute ischaemic strokes and TIAs (not done);</LI>
<LI>all acute ischaemic strokes (not done);</LI>
<LI>all haemorrhagic strokes (not done).</LI>
</OL>
<LI>Intervention type:</LI>
<OL>
<LI>any drug versus control;</LI>
<LI>statins (any dose) versus control (not done);</LI>
<LI>statins (high dose) versus control (not done);</LI>
<LI>non-statin drugs versus control;</LI>
<LI>diet versus none (not done).</LI>
</OL>
<LI>Previous cardiovascular event (not done).</LI>
<LI>Optimal cholesterol control versus standard control (not done).</LI>
</OL>
<P>We had planned to perform a meta-regression to investigate the effect of lipid changes actually achieved if unbiased estimates had been obtainable. There was also insufficient information for an assessment of potential side effects from treatment.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-05-06 09:15:42 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY_DESCRIPTION MODIFIED="2009-05-06 09:15:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>We identified eight trials that met all of the inclusion criteria. Five of the studies investigated statins: pravastatin (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>; <LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>), simvastatin (<LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>; <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK>); and atorvastatin (<LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>). Two looked at the use of clofibrate (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>; <LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>), and the eighth used oestrogen as Premarin (<LINK REF="STD-VASCA-1966" TYPE="STUDY">VASCA 1966</LINK>). However, the data used here from three studies (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>; <LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>; <LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>) are sub-group analyses from the trials.</P>
<P>Of the trials where data from subgroups of the trial population were analysed, one trial only included patients with a history of MI or unstable angina (<LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>), another only recruited those who had had an acute MI (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>), whereas the third included adults with coronary disease, other occlusive arterial disease or diabetes (<LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>). The remaining trials also differed in their study populations. One study included patients who had experienced a cerebral infarct or TIA (<LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>), whereas another only included those whose symptoms lasted over 12 hours (<LINK REF="STD-VASCA-1966" TYPE="STUDY">VASCA 1966</LINK>). The other trials recruited patients with any history of stroke or TIA as the inclusion event (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>; <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>), but certain sub-groups of stroke were excluded at entry in some trials, e.g. cardio-embolic strokes in <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>. In the <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK> study, statin treatment was started within 24 hours of onset of a minor stroke or TIA. Data on the time from stroke onset to randomisation were not reported in the trials but was in the order of several weeks to years. The effect this may have had in terms of outcome measures was also not recorded.</P>
<P>In addition, the studies differed in the length of follow up of the patients. The shortest reported length of follow up was 90 days for the <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK> study, followed by the VASCA trial, with an average follow up of under 17 months (<LINK REF="STD-VASCA-1966" TYPE="STUDY">VASCA 1966</LINK>). This increased to up to four years in one trial (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>), and up to four and a half years in another (<LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>). The four more recent trials reported that patients were followed for six years (<LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>, a median of five years (range 4.0 to 6.2 years) (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>), a median of 4.9 years (<LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>) and a mean of five years (<LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-05-06 09:15:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>All the trials identified were unconfounded parallel group randomised trials.</P>
<P>It was unclear whether allocation concealment was adequate in two trials (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>; <LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>) as details are not reported: neither study used an intention-to-treat analysis. Eleven patients were excluded from the former (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>): three because the diagnosis was incorrect and a further eight because they refused to co-operate during the follow-up period. The other trial (<LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>) excluded nine participants; eight were randomised to a hospital not continuing in the study, and one was illegible because of a concurrent malignancy. In neither case was it stated to which treatment group each of these participants had been randomised.</P>
<P>One trial matched patients pairwise according to identified potential risk factors: clinical status, duration of disease, age, sex, degree of hypertension, and serum cholesterol level (within 50 mg/100ml) (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>).</P>
<P>Another trial reported a slightly higher rate of cardiovascular disorders in the control group at baseline (<LINK REF="STD-VASCA-1966" TYPE="STUDY">VASCA 1966</LINK>) and some differences between the treatment groups were reported in a further study (<LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>), although it is not stated whether these were felt to be clinically important. The final studies (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>; <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK>; <LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>; <LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>; <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>) reported that, for the entire study populations in each trial, the two treatment groups were similar with respect to stroke risk factors.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-05-06 09:15:42 +0100" MODIFIED_BY="Hazel Fraser">
<SUBSECTION>
<HEADING LEVEL="3">All ischaemic or haemorrhagic strokes</HEADING>
<P>Seven of the studies reported stroke recurrence as an outcome measure for those with a previous history of stroke or TIA. Overall, using a fixed-effect analysis there was no evidence, at the 5% significance level, for a difference in outcome between the treatment and placebo groups. There was, however, some evidence of a difference between the two treatment groups (statins and fibrates: P = 0.03).</P>
<P>The treatment effects from the two trials of fibrates tended to favour the control group although this was not statistically significant (odds ratio (OR) 1.48, 95% confidence interval (CI) 0.94 to 2.30). For the studies involving statins only, there was borderline statistical difference favouring the active treatment group compared with the placebo groups in stroke recurrence (OR 0.88, 95% CI 0.77 to 1.00) (five studies) with no evidence of heterogeneity in the results (P = 0.25). However, analysis by type of subsequent stroke (two studies) showed evidence for a protective effect of statins for ischaemic stroke (OR 0.78, 95% CI 0.67 to 0.92) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>) but evidence for an increased risk of haemorrhagic stroke (OR 1.72, 95% CI 1.20 to 2.46) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
<P>There was also no evidence of a treatment effect on stroke recurrence for those with a previous history of stroke only (OR 0.97, 95% CI 0.71 to 1.31) (four studies) and, although both statin studies showed a tendency toward a protective effect (OR 0.73, 95% CI 0.44 to 1.22), there was no evidence of heterogeneity amongst all of the studies included with the overall results (P = 0.30) nor for difference between the type of intervention (P = 0.19).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">All-cause mortality, including sudden deaths</HEADING>
<P>Despite the reduction in serious cardiovascular events with statin therapy, there was no evidence that intervention reduced all-cause mortality in patients with a history of stroke or TIA (OR 1.00, 95% CI 0.83 to 1.20) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>) (three studies) and no evidence that treatment type influenced this outcome (test for subgroup differences P = 0.52), but this is based on only one trial in the statin group and two in the fibrate group.</P>
<P>For patients with a history of stroke only, OR 1.16, 95% CI 0.69 to 1.95 (one study).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Serious vascular events</HEADING>
<P>There was strong evidence for a reduction in subsequent vascular events in patients with a history of stroke or TIA with lipid-lowering therapy: OR 0.77, 95% CI 0.70 to 0.84, P &lt; 0.0001 (four studies). This effect was due to the positive results from the two large trials of statins (<LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>; <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>), though not from the early statin intervention trial (<LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK>). For patients with a history of stroke or TIA , subsequent serious vascular events were significantly reduced (OR 0.74, 95% CI 0.67 to 0.82) in those on statins in the three studies where data were available.</P>
<P>For patients with a history of stroke only, the results were only available from a trial of oestrogen where no beneficial effect was seen: OR 1.03, 95% CI 0.72 to 1.48.</P>
<P>The effects of treatment on outcome measures could not be calculated in relation to lipid level changes between treatment and control groups for any of the outcome measures. The decision was taken post hoc to analyse the data according to non-statin drug type (i.e. fibrate and oestrogen) where possible. This was done to provide more information but should be interpreted in the light of it being a post hoc decision.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-05-06 09:16:03 +0100" MODIFIED_BY="Hazel Fraser">
<P>Since publication of the previous Cochrane analysis in 2002, there have been three important trials of the effects of altering lipid levels pharmacologically post stroke on stroke recurrence, development of serious vascular events, and death, all of which have involved the use of statins. The Heart Protection Study (<LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>) enrolled 3280 patients aged 40 to 80 years, 64% with a history of ischaemic stroke and 46% with TIA (those with cerebral haemorrhage were excluded) and a baseline total cholesterol (TC) &gt; 3.5 mmol/l with a mean of 5.9 mmol/l. They were randomised to simvastatin 40 mg daily or placebo and followed up for 4.8 years. The <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK> trial was the first to assess the effects of a statin (atorvastatin 80 mg daily) exclusively in stroke patients, enrolling 4731 participants aged over 18 years with cerebral infarction (67%), TIA (30%) and cerebral haemorrhage (2%). Baseline TC was &lt; 5.5 mmol/l and follow up was for 4.9 years. Most recently the <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK> study was published, having been prematurely stopped because of recruitment problems. This trial recruited minor stroke and TIA patients within 24 hours of symptom onset, of whom 199 patients were randomised to simvastatin 40 mg and 193 to placebo with a 90-day follow up. Overall the trials involving both statins and fibrates failed to demonstrate that therapy reduced stroke recurrence in patients with a history of cerebrovascular disease, although the trials showed some degree of heterogeneity in terms of the outcome measure between the different drug classes.<BR/>
<BR/>The two trials that excluded TIA patients, randomising only patients with a history of stroke and CHD, to pravastatin or placebo (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>; <LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>) similarly failed to offer point estimates of treatment effect favouring the use of statins. However, these were both small subgroup analyses from large trials, and included only 821 patients. The estimated odds ratio for treatment effect had a wide confidence interval (OR 0.73, 95% CI 0.44 to 1.22). However, these two statin-based trials comprised patients who had a history of CHD and who are likely to be prescribed statins to reduce the risk of further heart disease irrespective of their effectiveness in preventing further stroke episodes. These two trials were also limited in their applicability as the study population was aged 75 years or under but did include patients with TIA.</P>
<P>The results from the important <LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK> study show evidence of benefit from statin therapy in the sub-group of patients with a history of cerebrovascular disease in preventing subsequent major vascular events (i.e. major coronary event and coronary or non-coronary revascularisation) but, interestingly, not stroke. There was evidence that those with a history of cerebrovascular disease were more likely to develop subsequent cerebral haemorrhage with simvastatin than those without a stroke history. However, these data are also limited by the relatively small number of stroke events in this sub-group and that the results apply only to those under the age of 80 years, who have had an ischaemic, but not haemorrhagic, stroke or TIA and who are not severely disabled after their initial stroke. We were unable to differentiate further between stroke subtype, e.g. large artery events versus lacunar and cardio-embolic events, as well as between infarct and haemorrhagic strokes. The effect of statin treatment on major vascular event rates were not reported in the CARE and LIPID studies. No other lipid-lowering trials to date have shown this benefit in study populations, including both those with and without a history of cerebrovascular disease (<LINK REF="REF-ALLHAT-2002" TYPE="REFERENCE">ALLHAT 2002</LINK>; <LINK REF="REF-PROSPER-2002" TYPE="REFERENCE">PROSPER 2002</LINK>). The PROSPER Trial (<LINK REF="REF-PROSPER-2002" TYPE="REFERENCE">PROSPER 2002</LINK>) investigated the effects of pravastatin in older people (aged 70 to 82 years) with a history of, or risk factors for, vascular disease (of whom 11% had a previous stroke) and although it showed evidence of a reduction in the risk of subsequent coronary artery disease there was no evidence of a benefit in stroke reduction (the data relating to those with a history of stroke have not been presented separately). Similarly, major vascular event rates were not reported in the stroke sub-group of the <LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK> and <LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK> studies. The ALLHAT (<LINK REF="REF-ALLHAT-2002" TYPE="REFERENCE">ALLHAT 2002</LINK>) and ASCOT (<LINK REF="REF-ASCOT-2003" TYPE="REFERENCE">ASCOT 2003</LINK>) studies also showed no evidence for a reduction in stroke, nor in coronary heart disease, although in this trial the patients in the usual care group experienced an 11% fall in cholesterol levels. Subgroup analyses from these trials of patients with a previous history of cerebrovascular disease may add further information but are not currently available.</P>
<P>The <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK> study is unique in that it is the first trial of statins solely in stroke patients without evidence of CHD and included those with a history of cerebral haemorrhage, though the numbers in this group were too small to allow for useful analysis. However, those with presumed cardio-embolic stroke including those with atrial fibrillation were excluded, reducing the generalisability of the results as this might be expected to involve at least 20% of the stroke population. Non-fatal or fatal stroke were significantly reduced by atorvastatin, though this was mainly due to a reduction in fatal stroke; however, although the odds of ischaemic stroke were reduced by 22% with atorvastatin, the odds of cerebral haemorrhage were significantly increased by 66%. This is the only study to date that has shown drug induced changes in serum lipids are associated with a reduction in stroke risk. Active treatment also reduced the odds of any coronary event by 42% and the odds of all major cardiovascular events by 20%.</P>
<P>It is impossible to assess in this review if the effects of time from stroke or TIA onset to treatment influences subsequent events as these data are not available, though the range is large, from weeks to years. The <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK> Trial data, however, may indicate that very early intervention (within 24 hours of symptom onset) with statins following stroke could have an adverse effect, there being a non-significant increase in stroke recurrence for the simvastatin-treated patients; this needs further clarification.</P>
<P>Amongst the eight trials that have aimed to alter lipid levels following stroke or TIA, three different classes of drugs have been used: the majority have used statins (<LINK REF="STD-CARE" TYPE="STUDY">CARE</LINK>; <LINK REF="STD-FASTER" TYPE="STUDY">FASTER</LINK>; <LINK REF="STD-HPS" TYPE="STUDY">HPS</LINK>; <LINK REF="STD-LIPID" TYPE="STUDY">LIPID</LINK>; <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK>); two used fibrates (<LINK REF="STD-Acheson-1972" TYPE="STUDY">Acheson 1972</LINK>; <LINK REF="STD-VACSA-1973" TYPE="STUDY">VACSA 1973</LINK>) and one oestrogen (<LINK REF="STD-VASCA-1966" TYPE="STUDY">VASCA 1966</LINK>). However, because of the way the data are presented it is difficult to directly compare outcome measures between trials for all stroke events (the outcome measure where most information is available). There was some evidence for differences in outcome between drug groups: statin therapy resulting in a borderline significant 12% reduction in the odds of subsequent cerebrovascular events compared to a 48% increase in odds with fibrates. Even in the statin trials, there was a diversity of effect on stroke sub-type, with a significant 72% increase in the odds of cerebral haemorrhage with treatment which partially offset the 22% reduction in odds for ischaemic stroke (there being a 10:1 ratio of ischaemic to haemorrhagic events as would be expected). For serious vascular events, a similar difference was seen between statins and fibrates, although the numbers are much smaller than for stroke recurrence; again statins resulted in a 26% reduction in the odds compared with a 27% increase with fibrates, although data were limited to the VACSA trial for the latter drug group. It was not possible to assess if these effects were similar for those who had a previous history of stroke only as opposed to TIA: the data from trials that enrolled only stroke patients, as opposed to those with recruiting either stroke or TIA, appear not to differ in outcomes. Statin therapy, however, appeared to have no benefit in reducing all-cause mortality.</P>
<P>It is not possible to obtain sufficient data on baseline lipid levels or the size of the lipid changes achieved during any of the trials in relation to outcomes. This would be useful information in order to investigate whether the potential neuroprotective effects of statins derive solely from their lipid-altering effects or by some other mechanisms, e.g. anti-inflammatory effects or endothelial protection. Some information on the recorded blood pressures of the patients and other potential risk factors for stroke recurrence, as well as other secondary preventative measures such as aspirin use, would also have been of interest.</P>
<P>Many important questions are still left unanswered regarding lipid-altering therapy in the post-stroke period. It was not possible to assess the effects of any of the lipid agents on those with a previous cerebral haemorrhage (the numbers in the <LINK REF="STD-SPARCL" TYPE="STUDY">SPARCL</LINK> study were too small and not reported separately) or TIA. It is unclear when after the cerebrovascular event therapy to alter lipid levels should be started, at what baseline lipid levels treatment should be commenced, what level of reduction should be aimed for or whether the very elderly (those aged over 80 years) stroke patient benefits to the same extent as a younger counterpart.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-04-17 16:45:18 +0100" MODIFIED_BY="Hazel Fraser">
<IMPLICATIONS_PRACTICE MODIFIED="2009-04-17 16:44:45 +0100" MODIFIED_BY="Hazel Fraser">
<P>There is good evidence for a benefit of statin therapy in those under the age of 80 years with a previous non-disabling stroke or TIA (but not cerebral haemorrhage) who have baseline total cholesterol levels &gt; 3.5 mmols/l in terms of reducing subsequent serious vascular events. The data also suggest a marginal benefit of statins in reducing future cerebrovascular events, but not overall mortality. In view of this evidence it is recommended that all ischaemic stroke or TIA patients aged at least up to 80 years should receive statin therapy as part of a secondary prevention programme</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-04-17 16:45:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>Further work is needed to assess the potential role of statins for those patients with a previous cerebral haemorrhage, when after the cerebrovascular event therapy to alter lipid levels should be started, at what baseline lipid levels treatment should be commenced, what level of reduction should be aimed for or whether the very elderly (those aged over 80 years) stroke patient benefits to the same extent as a younger counterpart.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-05-06 09:16:04 +0100" MODIFIED_BY="Hazel Fraser"/>
<CONFLICT_OF_INTEREST MODIFIED="2009-04-20 12:14:10 +0100" MODIFIED_BY="Hazel Fraser">
<P>JF Potter has received honoraria from MSD, Sanofi and Boehringer Ingelheim for attending Advisory Boards or giving lectures at meetings sponsored by these companies.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-04-17 14:42:50 +0100" MODIFIED_BY="Hazel Fraser">
<P>BN Manktelow: writing of review, literature search, data extraction, data analysis.<BR/>JF Potter: writing of review, data extraction.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-05-06 09:16:53 +0100" MODIFIED_BY="Hazel Fraser">
<STUDIES MODIFIED="2009-04-17 14:58:55 +0100" MODIFIED_BY="Hazel Fraser">
<INCLUDED_STUDIES MODIFIED="2009-04-17 14:58:55 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-Acheson-1972" MODIFIED="2009-04-17 14:54:37 +0100" MODIFIED_BY="Hazel Fraser" NAME="Acheson 1972" YEAR="1972">
<REFERENCE MODIFIED="2009-04-17 14:54:28 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;FINAL REPORT IS ACHESON 1972&lt;/p&gt;" NOTES_MODIFIED="2009-04-17 14:54:28 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Acheson J, Hutchinson EC</AU>
<TI>A controlled trial of atromid in cerebral vascular disease. A preliminary report</TI>
<SO>Journal of Atherosclerosis Research</SO>
<YR>1963</YR>
<VL>3</VL>
<PG>711-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:54:37 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Acheson J, Hutchinson EC</AU>
<TI>Controlled trial of clofibrate in cerebral vascular disease</TI>
<SO>Atherosclerosis</SO>
<YR>1972</YR>
<VL>15</VL>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CARE" MODIFIED="2009-04-17 14:55:23 +0100" MODIFIED_BY="Hazel Fraser" NAME="CARE" YEAR="1999">
<REFERENCE MODIFIED="2009-04-17 14:54:53 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al</AU>
<TI>Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) Study</TI>
<SO>Circulation</SO>
<YR>1999</YR>
<VL>99</VL>
<NO>2</NO>
<PG>216-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99110724"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:55:09 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacks FM, Pfeffer MA, Moye L, Brown LE, Hamm P, Cole TG, et al</AU>
<TI>Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events Trial (CARE)</TI>
<SO>American Journal of Cardiology</SO>
<YR>1991</YR>
<VL>68</VL>
<PG>1436-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:55:23 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al</AU>
<TI>The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>335</VL>
<PG>1001-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-FASTER" MODIFIED="2009-04-17 14:55:52 +0100" MODIFIED_BY="Hazel Fraser" NAME="FASTER" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy J, Eliasziw M, Hill MD, Buchan AM</AU>
<TI>The Fast Assessment of Stroke and Transient Ischemic Attack to Prevent Early Recurrence (FASTER) Trial</TI>
<SO>Seminars in Cerebrovascular Diseases and Stroke</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>1</NO>
<PG>25-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:55:52 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM</AU>
<TI>Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial</TI>
<SO>Lancet Neurology</SO>
<YR>2007</YR>
<VL>6</VL>
<PG>961-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-HPS" MODIFIED="2009-04-17 14:56:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="HPS" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collins R, Peto R</AU>
<TI>MRC/BHF Heart Protection Study</TI>
<SO>Stroke</SO>
<YR>1994</YR>
<VL>25</VL>
<NO>2</NO>
<PG>543</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:56:09 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Heart Protection Study Collaborative Group</AU>
<TI>Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>363</VL>
<PG>757-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:56:17 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>7-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:56:29 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heart Protection Study Collaborative Group</AU>
<TI>The MRC/BHF Heart Protection Study: preliminary results</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>2002</YR>
<VL>56</VL>
<NO>1</NO>
<PG>53-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:56:43 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>MRC/BHF Heart Protection Study</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experence</TI>
<SO>European Heart Journal</SO>
<YR>1999</YR>
<VL>20</VL>
<PG>725-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-08 14:46:13 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="OTHER">
<TI>MRC/BHF Heart Protection Study</TI>
<SO>http://www.ctsu.ox.ac.uk/~hps/</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-LIPID" MODIFIED="2009-04-17 14:57:32 +0100" MODIFIED_BY="Hazel Fraser" NAME="LIPID" YEAR="2000">
<REFERENCE MODIFIED="2009-04-08 14:47:32 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="CORRESPONDENCE">
<AU>Kirby A</AU>
<SO>Personal communication.</SO>
<YR>Unpublished</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:57:20 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The LIPID Study Group</AU>
<TI>Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>1379-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:57:32 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>White HD, Simes J, Anderson NE, Hankey GJ, Watson JDG, Hunt D, et al</AU>
<TI>Pravastatin therapy and the risk of stroke</TI>
<SO>New England Journal of Medicine</SO>
<YR>2000</YR>
<VL>343</VL>
<NO>5</NO>
<PG>317-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-SPARCL" MODIFIED="2009-04-17 14:58:13 +0100" MODIFIED_BY="Hazel Fraser" NAME="SPARCL" YEAR="">
<REFERENCE MODIFIED="2009-04-17 14:57:53 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amarenco P, Bogousslavsky J, Callahan A, Goldstein L, Hennerici M, Sillesen H, et al</AU>
<TI>Effect of atorvastatin compared with placebo on cerebrovascular end points in patients with previous stroke or transient ischemic attack - The SPARCL Study</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1999</YR>
<VL>9 Suppl 1</VL>
<PG>108</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:58:01 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SPARCL Investigators</AU>
<TI>Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>389-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:58:13 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>SPARCL Investigators</AU>
<TI>High-dose atorvastatin after stroke or transient ischemic attack</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<NO>6</NO>
<PG>549-59</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="16899775"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Welch KMA</AU>
<TI>Stroke prevention by aggresive reduction in cholesterol levels (SPARCL)</TI>
<SO>Stroke</SO>
<YR>2000</YR>
<VL>31</VL>
<NO>11</NO>
<PG>2541</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VACSA-1973" MODIFIED="2009-04-17 14:58:44 +0100" MODIFIED_BY="Hazel Fraser" NAME="VACSA 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hirsch SB, Wechsler AF, Tourtellotte WW</AU>
<TI>Clofibrate for the treatment of occlusive cerebrovascular disease</TI>
<SO>New England Journal of Medicine</SO>
<YR>1972</YR>
<VL>287</VL>
<NO>13</NO>
<PG>671</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73015139"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2009-04-17 14:58:44 +0100" MODIFIED_BY="Hazel Fraser" NOTES="&lt;p&gt;.The treatment of cerebrovascular disease with Clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke 1973;4:684-693.&lt;/p&gt;" NOTES_MODIFIED="2009-04-17 14:58:44 +0100" NOTES_MODIFIED_BY="Hazel Fraser" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>The Veterans Administration Cooperative Study Group</AU>
<TI>The treatment of cerebrovascular disease with clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section</TI>
<SO>Stroke</SO>
<YR>1973</YR>
<VL>4</VL>
<PG>684-93</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="73232915"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-VASCA-1966" MODIFIED="2009-04-17 14:58:55 +0100" MODIFIED_BY="Hazel Fraser" NAME="VASCA 1966" YEAR="1966">
<REFERENCE MODIFIED="2009-04-17 14:58:55 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Veterans Administration Cooperative Study of Atherosclerosis</AU>
<TI>An evaluation of estrogenic substances in the treatment of cerebral vascular disease</TI>
<SO>Circulation</SO>
<YR>1966</YR>
<VL>33</VL>
<NO>5 Suppl</NO>
<PG>II3-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="91029891"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES/>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-04-17 14:54:02 +0100" MODIFIED_BY="Hazel Fraser">
<STUDY DATA_SOURCE="PUB" ID="STD-J_x002d_STARS" MODIFIED="2009-04-17 14:54:02 +0100" MODIFIED_BY="Hazel Fraser" NAME="J-STARS" YEAR="2006">
<REFERENCE MODIFIED="2009-04-17 14:54:02 +0100" MODIFIED_BY="Hazel Fraser" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kohriyama T, Nomura E, Matsumoto M, Ohtsuki T</AU>
<TI>J-STARS (Japan Statin Treatment Against Recurrent Stroke)</TI>
<SO>Nippon Rinsho - Japanese Journal of Clinical Medicine</SO>
<YR>2006</YR>
<VL>64 Suppl 7</VL>
<PG>511-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-05-06 09:16:53 +0100" MODIFIED_BY="Hazel Fraser">
<ADDITIONAL_REFERENCES MODIFIED="2009-05-06 09:16:53 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-ALLHAT-2002" NAME="ALLHAT 2002" TYPE="JOURNAL_ARTICLE">
<AU>ALLHAT Collaborative Research Group</AU>
<TI>Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2002</YR>
<VL>288</VL>
<NO>23</NO>
<PG>2998-3007</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ASCOT-2003" MODIFIED="2009-04-17 14:44:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="ASCOT 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sever PS, Dahlof B, Poulter NR, for the ASCOT investigators</AU>
<TI>Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>361</VL>
<PG>1149-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atkins-1993" MODIFIED="2008-09-03 12:45:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="Atkins 1993" TYPE="JOURNAL_ARTICLE">
<AU>Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Larson EB</AU>
<TI>Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>199</VL>
<NO>2</NO>
<PG>136-45</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="93290061"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blauw-1997" MODIFIED="2008-09-03 12:45:51 +0100" MODIFIED_BY="Hazel Fraser" NAME="Blauw 1997" TYPE="JOURNAL_ARTICLE">
<AU>Blauw GJ, Lagaay AM, Smelt AHM, Westendorp RGJ</AU>
<TI>Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors</TI>
<SO>Stroke</SO>
<YR>1997</YR>
<VL>28</VL>
<NO>5</NO>
<PG>946-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97302269"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bucher-1998" MODIFIED="2008-09-03 12:45:55 +0100" MODIFIED_BY="Hazel Fraser" NAME="Bucher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Bucher HC, Griffith LE, Guyatt GH</AU>
<TI>Effect of HMGcoA reductase inhibitors on stroke: a meta-analysis of randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1998</YR>
<VL>128</VL>
<NO>2</NO>
<PG>89-95</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98085833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Butterworth-1997" MODIFIED="2008-09-03 12:46:03 +0100" MODIFIED_BY="Hazel Fraser" NAME="Butterworth 1997" TYPE="JOURNAL_ARTICLE">
<AU>Butterworth RJ, Marshall WJ, Bath PMW</AU>
<TI>Changes in serum lipid measurements following acute ischemic stroke</TI>
<SO>Cerebrovascular Diseases</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Byington-2001" MODIFIED="2009-04-17 14:45:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Byington 2001" TYPE="JOURNAL_ARTICLE">
<AU>Byington RP, Davis BR, Plehn JF, White HD, Baker J, Cobbe SM, et al</AU>
<TI>Reduction of stroke events with Pravastatin: the Prospective Pravastatin Pooling (PPP) Project</TI>
<SO>Circulation</SO>
<YR>2001</YR>
<VL>103</VL>
<NO>3</NO>
<PG>387-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Candelise-1986" MODIFIED="2009-05-06 09:16:28 +0100" MODIFIED_BY="Hazel Fraser" NAME="Candelise 1986" TYPE="JOURNAL_ARTICLE">
<AU>Candelise L, Vigotti M, Fieschi C, Brambilla GL, Bono G, Conforti P, et al</AU>
<TI>Italian multicenter study on reversible cerebral ischemic attacks: VI - prognostic factors and follow-up results</TI>
<SO>Stroke</SO>
<YR>1986</YR>
<VL>17</VL>
<NO>5</NO>
<PG>842-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87020005"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Crouse-1997" MODIFIED="2008-09-03 12:46:34 +0100" MODIFIED_BY="Hazel Fraser" NAME="Crouse 1997" TYPE="JOURNAL_ARTICLE">
<AU>Crouse JR 3rd, Byington RP, Hoen HM, Furberg CD</AU>
<TI>Reductase inhibitor monotherapy and stroke prevention</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1997</YR>
<VL>157</VL>
<NO>12</NO>
<PG>1305-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97344622"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-CTT-2005" MODIFIED="2009-04-17 14:46:28 +0100" MODIFIED_BY="Hazel Fraser" NAME="CTT 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cholesterol Treatment Trialists' (CTT) Collaboration</AU>
<TI>Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>1267-78</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95282720"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Di-Mascio-2000" NAME="Di Mascio 2000" TYPE="JOURNAL_ARTICLE">
<AU>Di Mascio R, Marchioli R, Tognoni G</AU>
<TI>Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials</TI>
<SO>Cerebrovacular Diseases</SO>
<YR>2000</YR>
<VL>10</VL>
<PG>85-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dyker-1997" MODIFIED="2009-04-17 14:46:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="Dyker 1997" TYPE="JOURNAL_ARTICLE">
<AU>Dyker AG, Weir CJ, Lees KR</AU>
<TI>Influence of cholesterol on survival after stroke: retrospective study</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>1584-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97329696"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eliasziw-1995" MODIFIED="2008-09-03 12:46:42 +0100" MODIFIED_BY="Hazel Fraser" NAME="Eliasziw 1995" TYPE="JOURNAL_ARTICLE">
<AU>Eliasziw M, Streifler JY, Spence JD, Fox AJ, Hachinski VC, Barnett HJM</AU>
<TI>Prognosis for patients following a transient ischemic attack with and without a cerebral infarction on brain CT</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<PG>428-31</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95206518"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-ESCHD-1998" MODIFIED="2009-04-17 14:47:04 +0100" MODIFIED_BY="Hazel Fraser" NAME="ESCHD 1998" TYPE="JOURNAL_ARTICLE">
<AU>Eastern Stroke and Coronary Heart Disease Collaborative Research Group</AU>
<TI>Blood pressure, cholesterol, and stroke in eastern Asia</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>1801-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hebert-1995" MODIFIED="2008-09-03 12:46:48 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hebert 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hebert PR, Gaziano JM, Hennekens CH</AU>
<TI>An overview of trials of cholesterol lowering and risk of stroke</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1995</YR>
<VL>155</VL>
<NO>1</NO>
<PG>50-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95100811"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hebert-1997" MODIFIED="2008-09-03 12:46:50 +0100" MODIFIED_BY="Hazel Fraser" NAME="Hebert 1997" TYPE="JOURNAL_ARTICLE">
<AU>Hebert PR, Gaziano JM, Chan KS, Hennekens CH</AU>
<TI>Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1997</YR>
<VL>278</VL>
<NO>4</NO>
<PG>313-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97372174"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-JBS2-2005" MODIFIED="2009-04-17 14:47:43 +0100" MODIFIED_BY="Hazel Fraser" NAME="JBS2 2005" TYPE="JOURNAL_ARTICLE">
<AU>British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association</AU>
<TI>JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice</TI>
<SO>Heart</SO>
<YR>2005</YR>
<VL>91 Suppl 5</VL>
<PG>v1-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jorgensen-1997" MODIFIED="2009-04-17 14:47:55 +0100" MODIFIED_BY="Hazel Fraser" NAME="Jorgensen 1997" TYPE="JOURNAL_ARTICLE">
<AU>Jorgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS</AU>
<TI>Stroke recurrence: predictors, severity, and prognosis. The Copenhagen Stroke Study</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<PG>891-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97264001"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Law-2003" MODIFIED="2009-04-17 14:48:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Law 2003" TYPE="JOURNAL_ARTICLE">
<AU>Law MR, Wald NJ, Rudnicka AR</AU>
<TI>Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>326</VL>
<PG>1423-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marshall-1961" MODIFIED="2009-05-06 09:16:53 +0100" MODIFIED_BY="Hazel Fraser" NAME="Marshall 1961" TYPE="JOURNAL_ARTICLE">
<AU>Marshall J, Kaeser AC</AU>
<TI>Survival after non-haemorrhagic cerebrovascular accidents: a prospective study</TI>
<SO>British Medical Journal</SO>
<YR>1961</YR>
<PG>73-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNaughton-2002" NAME="McNaughton 2002" TYPE="JOURNAL_ARTICLE">
<AU>McNaughton H</AU>
<TI>Lowering lipids after a stroke or transient ischaemic attack</TI>
<SO>Hospital Medicine</SO>
<YR>2002</YR>
<VL>63</VL>
<NO>2</NO>
<PG>88-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mendez-1987" MODIFIED="2008-09-03 12:46:58 +0100" MODIFIED_BY="Hazel Fraser" NAME="Mendez 1987" TYPE="JOURNAL_ARTICLE">
<AU>Mendez I, Hachinski V, Wolfe B</AU>
<TI>Serum lipids after stroke</TI>
<SO>Neurology</SO>
<YR>1987</YR>
<VL>37</VL>
<PG>507-11</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87145065"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moroney-1997" MODIFIED="2008-09-03 12:47:02 +0100" MODIFIED_BY="Hazel Fraser" NAME="Moroney 1997" TYPE="JOURNAL_ARTICLE">
<AU>Moroney JT, Bagiella E, Tatemichi TK, Paik MC, Stern Y, Desmond DW</AU>
<TI>Dementia after stroke increases the risk of long-term stroke recurrence</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>48</VL>
<PG>1317-25</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97297833"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Neau-1997" MODIFIED="2009-04-17 14:48:54 +0100" MODIFIED_BY="Hazel Fraser" NAME="Neau 1997" TYPE="JOURNAL_ARTICLE">
<AU>Neau J-P, Ingrand P, Couderq C, Rosier MP, Bailbe M, Dumas P, et al</AU>
<TI>Recurrent intracerebral hemorrhage</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<PG>106-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="97365340"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Passero-1995" MODIFIED="2008-09-03 12:47:05 +0100" MODIFIED_BY="Hazel Fraser" NAME="Passero 1995" TYPE="JOURNAL_ARTICLE">
<AU>Passero S, Burgalassi L, D'Andrea P, Battistini N</AU>
<TI>Recurrence of bleeding in patients with primary intracerebral hemorrhage</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>7</NO>
<PG>1189-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95328103"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Prencipe-1998" MODIFIED="2009-04-17 14:49:16 +0100" MODIFIED_BY="Hazel Fraser" NAME="Prencipe 1998" TYPE="JOURNAL_ARTICLE">
<AU>Prencipe M, Culasso F, Rasura M, Anzini A, Beccia M, Cao M, et al</AU>
<TI>Long-term prognosis after a minor stroke. 10-year mortality and major stroke recurrence rates in a hospital-based cohort</TI>
<SO>Stroke</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>126-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98106118"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-PROSPER-2002" MODIFIED="2009-04-17 14:49:37 +0100" MODIFIED_BY="Hazel Fraser" NAME="PROSPER 2002" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al</AU>
<TI>Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>1623-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-PSC-2007" MODIFIED="2009-04-17 14:49:49 +0100" MODIFIED_BY="Hazel Fraser" NAME="PSC 2007" TYPE="JOURNAL_ARTICLE">
<AU>Prospective Studies Collaboration</AU>
<TI>Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55000 vascular deaths</TI>
<SO>Lancet</SO>
<YR>2007</YR>
<VL>370</VL>
<PG>1829-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2008" MODIFIED="2009-04-17 15:46:19 +0100" MODIFIED_BY="Hazel Fraser" NAME="RevMan 2008" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2008</YR>
<EN>5.0</EN>
<PB>The Nordic Cochrane Centre. The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sandercock-2001" NAME="Sandercock 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sandercock P</AU>
<TI>Statins for stroke prevention?</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1548-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sorensen-1989" MODIFIED="2008-09-03 12:47:14 +0100" MODIFIED_BY="Hazel Fraser" NAME="Sorensen 1989" TYPE="JOURNAL_ARTICLE">
<AU>Sorensen PS, Marquardsen J, Pedersen H, Heltberg A, Munck O</AU>
<TI>Long-term prognosis and quality of life after reversible cerebral ischemic attacks</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1989</YR>
<VL>79</VL>
<PG>204-13</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="89244104"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Latum-1995" MODIFIED="2008-09-03 12:47:17 +0100" MODIFIED_BY="Hazel Fraser" NAME="van Latum 1995" TYPE="JOURNAL_ARTICLE">
<AU>van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A</AU>
<TI>Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation</TI>
<SO>Stroke</SO>
<YR>1995</YR>
<VL>26</VL>
<NO>5</NO>
<PG>801-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95259107"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vauthey-2000" MODIFIED="2009-04-17 14:50:20 +0100" MODIFIED_BY="Hazel Fraser" NAME="Vauthey 2000" TYPE="JOURNAL_ARTICLE">
<AU>Vauthey C, de Freitas GR, van Melle G, Devuyst G, Bogousslavsky J</AU>
<TI>Better outcome after stroke with higher serum cholesterol levels</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>10</NO>
<PG>1944-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Williams-2004" MODIFIED="2009-04-17 14:50:34 +0100" MODIFIED_BY="Hazel Fraser" NAME="Williams 2004" TYPE="JOURNAL_ARTICLE">
<AU>Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al</AU>
<TI>Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 - BHS IV</TI>
<SO>Journal of Human Hypertension</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>3</NO>
<PG>139-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-1998" MODIFIED="2009-04-17 14:50:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Wood 1998" TYPE="JOURNAL_ARTICLE">
<AU>Wood D, Durrington P, McInnes, Paulter N, Rees A, Wray R</AU>
<TI>Joint British recommendations on prevention of coronary heart disease in clinical practice</TI>
<SO>Heart</SO>
<YR>1998</YR>
<VL>80 Suppl 2</VL>
<PG>S1-29</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-04-17 14:52:59 +0100" MODIFIED_BY="Hazel Fraser">
<REFERENCE ID="REF-Manktelow-2002" MODIFIED="2009-04-17 14:52:59 +0100" MODIFIED_BY="Hazel Fraser" NAME="Manktelow 2002" TYPE="COCHRANE_REVIEW">
<AU>Manktelow BN, Gillies C, Potter J</AU>
<TI>Interventions in the management of serum lipids for preventing stroke recurrence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2009-04-17 14:52:59 +0100" MODIFIED_BY="Hazel Fraser">
<IDENTIFIER MODIFIED="2009-04-17 14:52:59 +0100" MODIFIED_BY="Hazel Fraser" TYPE="DOI" VALUE="Art. No.: CD002091. DOI: 10.1002/14651858.CD002091"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-05-06 09:16:08 +0100" MODIFIED_BY="Hazel Fraser">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-05-06 09:16:08 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-05-05 07:28:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Acheson-1972">
<CHAR_METHODS MODIFIED="2009-05-05 07:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>Parallel group, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:00:43 +0100" MODIFIED_BY="Hazel Fraser">
<P>106 patients (11 excluded from analysis: 3 incorrect diagnosis; 8 refused to co-operate)<BR/>Country: UK<BR/>Study years:1962 to 1969<BR/>Age: 43 to 76 years<BR/>Male: 68%<BR/>Inclusion: previous stroke or TIA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:02:18 +0100" MODIFIED_BY="Hazel Fraser">
<P>Clofibrate (250 mg capsules: 4 to 6 daily for females; 6 to 8 daily for males)<BR/>Placebo (corn oil for first 20 months of trial)<BR/>Follow up: between 4 months and 4 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:02:28 +0100" MODIFIED_BY="Hazel Fraser">
<P>Cerebral ischaemia<BR/>Stroke<BR/>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Matched pairs design</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-17 15:04:53 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-CARE">
<CHAR_METHODS MODIFIED="2009-04-17 15:02:35 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:04:04 +0100" MODIFIED_BY="Hazel Fraser">
<P>4159 patients (122 previous stroke: 211 previous stroke or TIA)<BR/>Country: USA<BR/>Study years: 1989 to 1996<BR/>Age: 21 to 75 years<BR/>Male: 86% (whole trial)<BR/>Inclusion: MI 3 to 20 months before randomisation, total cholesterol &lt; 240 mg/dl; LDL 115 to 174 mg/dl; triglycerides &#8804; 350 mg/dl</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:04:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Pravastatin (40 mg/d)<BR/>Matching placebo<BR/>Follow up: median 5.0 years (range 4.0 to 6.2)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:04:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Stroke symptoms lasting &#8805; 24 hours</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sub-group analysis of trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-05-06 09:16:08 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-FASTER">
<CHAR_METHODS MODIFIED="2009-05-06 09:16:08 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial<BR/>2 x 2 factorial design with clopidogrel</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:05:23 +0100" MODIFIED_BY="Hazel Fraser">
<P>392 patients<BR/>Country: Canada<BR/>Study years: 2003 to 2006<BR/>Age: 40 years or older<BR/>Male: 53%<BR/>Inclusion: TIA or minor stroke (NIHSS &lt; 4) within 24 hours of onset</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:06:21 +0100" MODIFIED_BY="Hazel Fraser">
<P>Simvastatin (40 mg/d)<BR/>Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:06:27 +0100" MODIFIED_BY="Hazel Fraser">
<P>Stroke within 90 days<BR/>Major vascular event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Trial stopped early because of low recruitment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-17 15:08:48 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-HPS">
<CHAR_METHODS MODIFIED="2009-04-17 15:06:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial<BR/>2 x 2 factorial design with antioxidant vitamin supplementation</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:07:52 +0100" MODIFIED_BY="Hazel Fraser">
<P>20,536 patients (3280 with previous cerebrovascular event)<BR/>Country: UK<BR/>Study years: 1994 to 2001<BR/>Age: around 40 to 80 years<BR/>Inclusion: non-fasting total cholesterol &#8805; 135 mg/dL, substantial 5-year risk from CHD</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:08:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>Simvastatin (40 mg/d)<BR/>Matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:08:44 +0100" MODIFIED_BY="Hazel Fraser">
<P>Stroke<BR/>Major cerebrovascular event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-17 15:08:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>Sub-group analysis of 2 x 2 factorial design trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-17 15:15:47 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-LIPID">
<CHAR_METHODS MODIFIED="2009-04-17 15:08:54 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:15:39 +0100" MODIFIED_BY="Hazel Fraser">
<P>9014 patients (369 with previous stroke)<BR/>Country: Australia and New Zealand<BR/>Study years: 1990 to 1996<BR/>Age: 31 to 75 years<BR/>Male: 83%<BR/>Inclusion: MI or unstable angina pectoris 3 to 36 months before randomisation; total cholesterol 155 to 271 mg/dl and fasting triglicerides &lt; 445 mg/dl</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:15:47 +0100" MODIFIED_BY="Hazel Fraser">
<P>Pravastatin (40 mg/d)<BR/>Matching placebo<BR/>Follow up: 6 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Sub-group analysis of trial</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-17 15:19:16 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-SPARCL">
<CHAR_METHODS MODIFIED="2009-04-17 15:18:48 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:19:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>4731 patients<BR/>Country: worldwide (205 sites)<BR/>Study years: 1998 to 2001<BR/>Age: over 18<BR/>Male: 59.8%<BR/>Inclusion: stroke or TIA in previous 6 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:19:12 +0100" MODIFIED_BY="Hazel Fraser">
<P>Atorvastatin (80 mg/d)<BR/>Matching placebo<BR/>Follow up: median 4.9 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:19:16 +0100" MODIFIED_BY="Hazel Fraser">
<P>Fatal or non-fatal stroke</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-17 15:20:14 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-VACSA-1973">
<CHAR_METHODS MODIFIED="2009-04-17 15:19:24 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:19:42 +0100" MODIFIED_BY="Hazel Fraser">
<P>541 patients (9 excluded from analysis: 8 hospital withdrew; 1 concurrent malignancy)<BR/>Country: USA<BR/>Study years: 1966 to 1970<BR/>Age: 70 or under<BR/>Male: 100%<BR/>Inclusion: history of cerebral infarction or TIA</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:20:02 +0100" MODIFIED_BY="Hazel Fraser">
<P>Clofibrate (500 mg x 4 daily)<BR/>Matching placebo<BR/>Follow up: up to 4.5 years</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:20:14 +0100" MODIFIED_BY="Hazel Fraser">
<P>Mortality<BR/>Cerebral infarction<BR/>Vascular event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-17 15:21:06 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-VASCA-1966">
<CHAR_METHODS MODIFIED="2009-04-17 15:20:20 +0100" MODIFIED_BY="Hazel Fraser">
<P>Parallel group, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 15:20:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>582 patients<BR/>Country: USA<BR/>Study years: 1962 to 1965<BR/>Age: not known<BR/>Male: 100%<BR/>Inclusion: history of cerebral infarct with symptoms lasting at least 12 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 15:20:58 +0100" MODIFIED_BY="Hazel Fraser">
<P>Mixed conjugated equine oestrogen (Premarin) (1.25 mg daily for 12 months then 2.5 mg)<BR/>Matching placebo<BR/>Follow up: average 16.7 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 15:21:06 +0100" MODIFIED_BY="Hazel Fraser">
<P>Cerebral infarct<BR/>Cerebral infarct &amp; MI<BR/>All cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CHD: coronary heart disease<BR/>MI: myocardial infarction<BR/>NIHSS: National Institutes of Health Stroke Scale<BR/>TIA: transient ischaemic attack</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-04-17 15:00:01 +0100" MODIFIED_BY="Hazel Fraser" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-04-17 15:00:01 +0100" MODIFIED_BY="Hazel Fraser" STUDY_ID="STD-J_x002d_STARS">
<CHAR_STUDY_NAME>
<P>Japan Statin Treatment Against Recurrent Stroke</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS MODIFIED="2009-04-17 14:59:33 +0100" MODIFIED_BY="Hazel Fraser">
<P>Ischaemic stroke, hyperlipidemia and total cholesterol 180 to 240 mg/dL, without statin in last 30 days<BR/>Age: 45 to 80 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-17 14:59:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>Pravastatin 10 mg/day or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-17 14:59:53 +0100" MODIFIED_BY="Hazel Fraser">
<P>Primary: cerebrovascular events<BR/>Secondary: stoke subtype, cardiovascular event, stroke death, cerebrovascular and cardiovascular death</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>1 March 2004</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-04-17 15:00:01 +0100" MODIFIED_BY="Hazel Fraser">
<P>Dr Masayasu Matsumoto, Hiroshima University<BR/>mack@hiroshima-u.ac.jp</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Expected completion February 2014</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Acheson-1972">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-CARE">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-FASTER">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-HPS">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-LIPID">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-SPARCL">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-VACSA-1973">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-VASCA-1966">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-04-17 16:22:01 +0100" MODIFIED_BY="Hazel Fraser">
<COMPARISON ID="CMP-001" MODIFIED="2009-04-17 16:22:01 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<NAME>Intervention versus control: history of stroke or TIA</NAME>
<DICH_OUTCOME CHI2="10.7968297973021" CI_END="1.035277513837367" CI_START="0.8089036200614501" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9151173305709297" ESTIMABLE="YES" EVENTS_1="561" EVENTS_2="598" I2="44.428132029095494" I2_Q="79.0378368182982" ID="CMP-001.01" LOG_CI_END="0.015056781264694957" LOG_CI_START="-0.09210322099465297" LOG_EFFECT_SIZE="-0.03852321986497901" METHOD="PETO" MODIFIED="2009-04-08 14:48:23 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.09486236945293136" P_Q="0.028951512559503345" P_Z="0.1587805292833137" Q="4.770500025841399" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4960" TOTAL_2="4891" WEIGHT="100.0" Z="1.4091848061208927">
<NAME>All ischaemic or haemorrhagic strokes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.414285163079914" CI_END="1.0001006655302684" CI_START="0.7736268278842392" DF="4.0" EFFECT_SIZE="0.8796048575576979" ESTIMABLE="YES" EVENTS_1="501" EVENTS_2="553" I2="26.12136451038715" ID="CMP-001.01.01" LOG_CI_END="4.3716283988908635E-5" LOG_CI_START="-0.11146847817006082" LOG_EFFECT_SIZE="-0.05571238094303596" NO="1" P_CHI2="0.24736744061866234" P_Z="0.05017989987992412" STUDIES="5" TAU2="0.0" TOTAL_1="4645" TOTAL_2="4579" WEIGHT="92.34655600225508" Z="1.9584272496102901">
<NAME>Statins</NAME>
<DICH_DATA CI_END="1.294552972594572" CI_START="0.30381540760786924" EFFECT_SIZE="0.6271404460236947" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.11211982629257185" LOG_CI_START="-0.5173902052283338" LOG_EFFECT_SIZE="-0.20263518946788098" ORDER="1" O_E="-3.412322274881518" SE="0.3697773086402923" STUDY_ID="STD-CARE" TOTAL_1="111" TOTAL_2="100" VAR="7.313402663911412" WEIGHT="2.8977446844134436"/>
<DICH_DATA CI_END="2.9986636316225947" CI_START="0.7491305255531261" EFFECT_SIZE="1.4987963378372928" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.47692775248071745" LOG_CI_START="-0.12544250594704284" LOG_EFFECT_SIZE="0.17574262326683732" ORDER="2" O_E="3.2321428571428577" SE="0.35383527158133515" STUDY_ID="STD-FASTER" TOTAL_1="199" TOTAL_2="193" VAR="7.987258762200533" WEIGHT="3.164742553478203"/>
<DICH_DATA CI_END="1.2354403925381094" CI_START="0.7880609082465984" EFFECT_SIZE="0.9867128649349397" ESTIMABLE="YES" EVENTS_1="169" EVENTS_2="170" LOG_CI_END="0.09182179642666864" LOG_CI_START="-0.10344021513335305" LOG_EFFECT_SIZE="-0.005809209353342195" ORDER="3" O_E="-1.01676829268294" SE="0.11469787215290246" STUDY_ID="STD-HPS" TOTAL_1="1645" TOTAL_2="1635" VAR="76.01324587008385" WEIGHT="30.118262221766233"/>
<DICH_DATA CI_END="1.1321363861219806" CI_START="0.4150231204048825" EFFECT_SIZE="0.6854653716215366" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="38" LOG_CI_END="0.053898748559212575" LOG_CI_START="-0.3819277086262995" LOG_EFFECT_SIZE="-0.16401448003354344" ORDER="4" O_E="-5.76229508196721" SE="0.25600661832652655" STUDY_ID="STD-LIPID" TOTAL_1="325" TOTAL_2="285" VAR="15.258000127091217" WEIGHT="6.045583813022467"/>
<DICH_DATA CI_END="0.9929461534085076" CI_START="0.7007456901771684" EFFECT_SIZE="0.8341479110919173" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="311" LOG_CI_END="-0.003074302271612239" LOG_CI_START="-0.1544395646173083" LOG_EFFECT_SIZE="-0.07875693344446023" ORDER="5" O_E="-22.939124920735594" SE="0.08891270437199456" STUDY_ID="STD-SPARCL" TOTAL_1="2365" TOTAL_2="2366" VAR="126.49470893620206" WEIGHT="50.12022272957474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6120446083807879" CI_END="2.304394000368527" CI_START="0.9445090248859391" DF="1.0" EFFECT_SIZE="1.4753036739061844" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="45" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.36255673584357334" LOG_CI_START="-0.02479388799155186" LOG_EFFECT_SIZE="0.1688814239260107" NO="2" P_CHI2="0.4340192023093903" P_Z="0.08744100271758241" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="312" WEIGHT="7.653443997744912" Z="1.7090537006271196">
<NAME>Fibrates</NAME>
<DICH_DATA CI_END="2.5203824242722557" CI_START="0.5075731962628229" EFFECT_SIZE="1.1310519717910894" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.4014664424284927" LOG_CI_START="-0.294501320033803" LOG_EFFECT_SIZE="0.05348256119734489" ORDER="6" O_E="0.7368421052631575" SE="0.40881490876633847" STUDY_ID="STD-Acheson-1972" TOTAL_1="47" TOTAL_2="48" VAR="5.983379501385041" WEIGHT="2.3707577637594284"/>
<DICH_DATA CI_END="2.843071117567261" CI_START="0.9717448739147786" EFFECT_SIZE="1.6621491463377005" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="23" LOG_CI_END="0.4537877234191542" LOG_CI_START="-0.012447741652597433" LOG_EFFECT_SIZE="0.22066999088327838" ORDER="7" O_E="6.774436090225564" SE="0.27386902008592034" STUDY_ID="STD-VACSA-1973" TOTAL_1="268" TOTAL_2="264" VAR="13.332579569223812" WEIGHT="5.282686233985483"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.065787092628378" CI_END="1.2014896654419656" CI_START="0.8334018886700113" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.000661659301901" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="261" I2="3.1846017851082" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.07972003959199554" LOG_CI_START="-0.07914551967183579" LOG_EFFECT_SIZE="2.8725996007984705E-4" METHOD="PETO" MODIFIED="2009-04-17 16:22:01 +0100" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="0.3559755870003637" P_Q="0.5213864930625784" P_Z="0.9943446452634709" Q="0.41114982122261456" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2680" TOTAL_2="2678" WEIGHT="100.0" Z="0.007087995391398639">
<NAME>All-cause mortality, including sudden deaths</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2524064755383537" CI_START="0.8414208382927827" DF="0.0" EFFECT_SIZE="1.0265480536880829" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="211" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.09774530446013148" LOG_CI_START="-0.07498673662196624" LOG_EFFECT_SIZE="0.011379283919082635" NO="1" P_CHI2="1.0" P_Z="0.7962232484578223" STUDIES="1" TAU2="0.0" TOTAL_1="2365" TOTAL_2="2366" WEIGHT="84.58896325867886" Z="0.2582379796074702">
<NAME>Statins</NAME>
<DICH_DATA CI_END="1.2524064755383537" CI_START="0.8414208382927827" EFFECT_SIZE="1.0265480536880829" ESTIMABLE="YES" EVENTS_1="216" EVENTS_2="211" LOG_CI_END="0.09774530446013148" LOG_CI_START="-0.07498673662196624" LOG_EFFECT_SIZE="0.011379283919082635" ORDER="8" O_E="2.5451278799408215" SE="0.10146365596901744" STUDY_ID="STD-SPARCL" TOTAL_1="2365" TOTAL_2="2366" VAR="97.13572504705827" WEIGHT="84.58896325867886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6546372714057636" CI_END="1.3859440828822234" CI_START="0.5458379965119203" DF="1.0" EFFECT_SIZE="0.8697706257847431" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="50" I2="39.563793389568104" ID="CMP-001.02.02" LOG_CI_END="0.14174570864117228" LOG_CI_START="-0.26293623579493614" LOG_EFFECT_SIZE="-0.06059526357688192" NO="2" P_CHI2="0.19832901614490228" P_Z="0.5572356290869097" STUDIES="2" TAU2="0.0" TOTAL_1="315" TOTAL_2="312" WEIGHT="15.41103674132114" Z="0.5869524740466938">
<NAME>Fibrates</NAME>
<DICH_DATA CI_END="2.9864697166878367" CI_START="0.5984322124012449" EFFECT_SIZE="1.3368618776174377" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="20" LOG_CI_END="0.4751581152853184" LOG_CI_START="-0.22298503731674862" LOG_EFFECT_SIZE="0.12608653898428487" ORDER="9" O_E="1.7263157894736842" SE="0.410092743702795" STUDY_ID="STD-Acheson-1972" TOTAL_1="47" TOTAL_2="48" VAR="5.946149584487534" WEIGHT="5.178101347255628"/>
<DICH_DATA CI_END="1.2395171650512107" CI_START="0.3950265912084968" EFFECT_SIZE="0.6997444108062596" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="0.09325254533167826" LOG_CI_START="-0.403373668863621" LOG_EFFECT_SIZE="-0.15506056176597144" ORDER="10" O_E="-4.195488721804512" SE="0.29172069655772664" STUDY_ID="STD-VACSA-1973" TOTAL_1="268" TOTAL_2="264" VAR="11.750748094909124" WEIGHT="10.232935394065512"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.271874031618582" CI_END="0.8423286886554623" CI_START="0.6958769665978946" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7656089946832818" ESTIMABLE="YES" EVENTS_1="1026" EVENTS_2="1247" I2="70.79403436251762" I2_Q="84.11629523565806" ID="CMP-001.03" LOG_CI_END="-0.07451840753286719" LOG_CI_START="-0.15746753833611796" LOG_EFFECT_SIZE="-0.11599297293449258" METHOD="PETO" MODIFIED="2009-04-08 14:48:37 +0100" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="0.016391071565454274" P_Q="0.012102809104413192" P_Z="4.2177961444668706E-8" Q="6.2957604339571045" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4477" TOTAL_2="4458" WEIGHT="100.0" Z="5.481481173095677">
<NAME>Serious vascular events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.976113597661477" CI_END="0.819919761692224" CI_START="0.6735991536082953" DF="2.0" EFFECT_SIZE="0.743167045490176" ESTIMABLE="YES" EVENTS_1="959" EVENTS_2="1192" I2="49.699626258759665" ID="CMP-001.03.01" LOG_CI_END="-0.08622864610327782" LOG_CI_START="-0.17159846720834432" LOG_EFFECT_SIZE="-0.12891355665581106" NO="1" P_CHI2="0.13696150433740495" P_Z="3.2326237928579947E-9" STUDIES="3" TAU2="0.0" TOTAL_1="4209" TOTAL_2="4194" WEIGHT="94.40933453374174" Z="5.919326640110724">
<NAME>Statins</NAME>
<DICH_DATA CI_END="2.5924668295640254" CI_START="0.7018748004365125" EFFECT_SIZE="1.3489207310433509" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.41371320832840125" LOG_CI_START="-0.153740349877044" LOG_EFFECT_SIZE="0.12998642922567857" ORDER="1" O_E="2.6938775510204067" SE="0.3333250290302937" STUDY_ID="STD-FASTER" TOTAL_1="199" TOTAL_2="193" VAR="9.000448449122329" WEIGHT="2.1367958518808288"/>
<DICH_DATA CI_END="0.8987105620900209" CI_START="0.6608852083031218" EFFECT_SIZE="0.7706779593520754" ESTIMABLE="YES" EVENTS_1="406" EVENTS_2="488" LOG_CI_END="-0.04638015423629989" LOG_CI_START="-0.17987396824489899" LOG_EFFECT_SIZE="-0.11312706124059943" ORDER="2" O_E="-42.36280487804879" SE="0.07841492715368775" STUDY_ID="STD-HPS" TOTAL_1="1645" TOTAL_2="1635" VAR="162.63069326402726" WEIGHT="38.61014178565335"/>
<DICH_DATA CI_END="0.8054449070706057" CI_START="0.620585824260223" EFFECT_SIZE="0.7069990746462195" ESTIMABLE="YES" EVENTS_1="530" EVENTS_2="687" LOG_CI_END="-0.0939641602398032" LOG_CI_START="-0.20719814901591344" LOG_EFFECT_SIZE="-0.1505811546278583" ORDER="3" O_E="-78.37138025787362" SE="0.06651420552437146" STUDY_ID="STD-SPARCL" TOTAL_1="2365" TOTAL_2="2366" VAR="226.03265374908395" WEIGHT="53.66239689620756"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.8949801533019501" CI_START="0.8448665289664223" DF="0.0" EFFECT_SIZE="1.265308383193788" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="55" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.2776046658309601" LOG_CI_START="-0.07321189496961565" LOG_EFFECT_SIZE="0.10219638543067228" NO="2" P_CHI2="1.0" P_Z="0.2534896369189207" STUDIES="1" TAU2="0.0" TOTAL_1="268" TOTAL_2="264" WEIGHT="5.590665466258251" Z="1.141914363091623">
<NAME>Fibrates</NAME>
<DICH_DATA CI_END="1.8949801533019501" CI_START="0.8448665289664223" EFFECT_SIZE="1.265308383193788" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="55" LOG_CI_END="0.2776046658309601" LOG_CI_START="-0.07321189496961565" LOG_EFFECT_SIZE="0.10219638543067228" ORDER="14" O_E="5.541353383458649" SE="0.20607138438424125" STUDY_ID="STD-VACSA-1973" TOTAL_1="268" TOTAL_2="264" VAR="23.54857450750618" WEIGHT="5.590665466258251"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.04186367186564932" CI_END="0.9152767336811751" CI_START="0.6726593954142663" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7846460949464565" ESTIMABLE="YES" EVENTS_1="318" EVENTS_2="396" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.03844757725587659" LOG_CI_START="-0.17220478739041847" LOG_EFFECT_SIZE="-0.10532618232314754" METHOD="PETO" MODIFIED="2009-04-08 14:48:42 +0100" MODIFIED_BY="Hazel Fraser" NO="4" P_CHI2="0.8378799713581294" P_Q="1.0" P_Z="0.002023781671377531" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4010" TOTAL_2="4001" WEIGHT="100.0" Z="3.0867199424213747">
<NAME>Ischaemic strokes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0548180336069912" CI_START="0.6117127006775236" EFFECT_SIZE="0.8032718021075353" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="122" LOG_CI_END="0.023177546063618985" LOG_CI_START="-0.21345250237467864" LOG_EFFECT_SIZE="-0.09513747815552984" ORDER="1" O_E="-11.338414634146346" SE="0.1389976617902869" STUDY_ID="STD-HPS" TOTAL_1="1645" TOTAL_2="1635" VAR="51.75889675245315" WEIGHT="31.95174771061981"/>
<DICH_DATA CI_END="0.9353264585812742" CI_START="0.6438968433047281" EFFECT_SIZE="0.7760500976998024" ESTIMABLE="YES" EVENTS_1="218" EVENTS_2="274" LOG_CI_END="-0.029036780127666532" LOG_CI_START="-0.19118370402528242" LOG_EFFECT_SIZE="-0.1101102420764745" ORDER="2" O_E="-27.948002536461644" SE="0.09524590573767772" STUDY_ID="STD-SPARCL" TOTAL_1="2365" TOTAL_2="2366" VAR="110.23191896511723" WEIGHT="68.04825228938019"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.07668729101661997" CI_END="2.4630813139847376" CI_START="1.1971407888667294" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.71716484568797" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.39147874948910344" LOG_CI_START="0.07814522829480286" LOG_EFFECT_SIZE="0.2348119888919532" METHOD="PETO" NO="5" P_CHI2="0.7818379318365509" P_Q="1.0" P_Z="0.003307718860204476" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4010" TOTAL_2="4001" WEIGHT="100.0" Z="2.937592119810632">
<NAME>Haemorrhagic strokes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.747426870071704" CI_START="0.9310531458432569" EFFECT_SIZE="1.8679008475285328" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.5737331664744967" LOG_CI_START="-0.031025528161833148" LOG_EFFECT_SIZE="0.2713538191563319" ORDER="1" O_E="4.951219512195124" SE="0.3552382508331989" STUDY_ID="STD-HPS" TOTAL_1="1645" TOTAL_2="1635" VAR="7.92429352762945" WEIGHT="26.844138857422585"/>
<DICH_DATA CI_END="2.5384715690117834" CI_START="1.0920286409663975" EFFECT_SIZE="1.6649575543057478" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="33" LOG_CI_END="0.40457230365142033" LOG_CI_START="0.03823402889119622" LOG_EFFECT_SIZE="0.2214031662713083" ORDER="2" O_E="11.009300359332066" SE="0.2151889159978619" STUDY_ID="STD-SPARCL" TOTAL_1="2365" TOTAL_2="2366" VAR="21.595347872371466" WEIGHT="73.15586114257742"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-04-08 14:50:09 +0100" MODIFIED_BY="Hazel Fraser" NO="2">
<NAME>Intervention versus control: history of stroke</NAME>
<DICH_OUTCOME CHI2="3.675411126705124" CI_END="1.3149070819308601" CI_START="0.7099958461547595" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9662186948358983" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="95" I2="18.376478261102896" I2_Q="40.270818730096494" ID="CMP-002.01" LOG_CI_END="0.11889506443758942" LOG_CI_START="-0.14874419212225393" LOG_EFFECT_SIZE="-0.014924563842332261" METHOD="PETO" MODIFIED="2009-04-08 14:49:57 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="0.29871449921684845" P_Q="0.18745389491259512" P_Z="0.8269695885618775" Q="3.3484470362358123" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="769" TOTAL_2="789" WEIGHT="100.0" Z="0.21858981370619232">
<NAME>All ischaemic or haemorrhagic strokes</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.32696409046931185" CI_END="1.2156575862059487" CI_START="0.4383768208406204" DF="1.0" EFFECT_SIZE="0.730011032705497" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="41" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.08481126460559835" LOG_CI_START="-0.3581524172224648" LOG_EFFECT_SIZE="-0.1366705763084332" NO="1" P_CHI2="0.5674523765420061" P_Z="0.22649316116629303" STUDIES="2" TAU2="0.0" TOTAL_1="233" TOTAL_2="258" WEIGHT="36.5059276793331" Z="1.2094418495231674">
<NAME>Statins</NAME>
<DICH_DATA CI_END="1.4019561356917098" CI_START="0.2553462950123428" EFFECT_SIZE="0.5983178962881684" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="16" LOG_CI_END="0.14673442566697523" LOG_CI_START="-0.5928704392275459" LOG_EFFECT_SIZE="-0.2230680067802853" ORDER="19" O_E="-2.721311475409836" SE="0.43444755874216845" STUDY_ID="STD-CARE" TOTAL_1="62" TOTAL_2="60" VAR="5.298162539617672" WEIGHT="13.09483743796501"/>
<DICH_DATA CI_END="1.5425091675603337" CI_START="0.4316013042575673" EFFECT_SIZE="0.8159344143669236" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="25" LOG_CI_END="0.18822775384565793" LOG_CI_START="-0.36491725159105326" LOG_EFFECT_SIZE="-0.08834474887269761" ORDER="20" O_E="-1.926829268292682" SE="0.32492011430546075" STUDY_ID="STD-LIPID" TOTAL_1="171" TOTAL_2="198" VAR="9.472111579546336" WEIGHT="23.41109024136809"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.567910963495084" CI_START="0.8365492904714931" DF="0.0" EFFECT_SIZE="1.4656684804231075" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.40957996147893055" LOG_CI_START="-0.07750846480425615" LOG_EFFECT_SIZE="0.16603574833733722" NO="2" P_CHI2="1.0" P_Z="0.18148349611550782" STUDIES="1" TAU2="0.0" TOTAL_1="241" TOTAL_2="244" WEIGHT="30.191452609090994" Z="1.3362012699441144">
<NAME>Fibrates</NAME>
<DICH_DATA CI_END="2.567910963495084" CI_START="0.8365492904714931" EFFECT_SIZE="1.4656684804231075" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="23" LOG_CI_END="0.40957996147893055" LOG_CI_START="-0.07750846480425615" LOG_EFFECT_SIZE="0.16603574833733722" ORDER="21" O_E="4.670103092783506" SE="0.28611815272534014" STUDY_ID="STD-VACSA-1973" TOTAL_1="241" TOTAL_2="244" VAR="12.215441695088842" WEIGHT="30.191452609090994"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.535912192512768" CI_START="0.527944030320379" DF="0.0" EFFECT_SIZE="0.9004863536630637" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="0.18636638796293103" LOG_CI_START="-0.27741211650298914" LOG_EFFECT_SIZE="-0.0455228642700291" MODIFIED="2009-04-08 14:49:57 +0100" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Z="0.7004105545491959" STUDIES="1" TAU2="0.0" TOTAL_1="295" TOTAL_2="287" WEIGHT="33.30261971157591" Z="0.38476632091912166">
<NAME>Oestrogen</NAME>
<DICH_DATA CI_END="1.535912192512768" CI_START="0.527944030320379" EFFECT_SIZE="0.9004863536630637" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.18636638796293103" LOG_CI_START="-0.27741211650298914" LOG_EFFECT_SIZE="-0.0455228642700291" ORDER="22" O_E="-1.412371134020617" SE="0.2724257892639039" STUDY_ID="STD-VASCA-1966" TOTAL_1="295" TOTAL_2="287" VAR="13.474217840647317" WEIGHT="33.30261971157591"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.9533090813520047" CI_START="0.6868521799737264" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.1582895150561887" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2907709691992554" LOG_CI_START="-0.16313671902387533" LOG_EFFECT_SIZE="0.06381712508768994" METHOD="PETO" MODIFIED="2009-04-08 14:50:05 +0100" MODIFIED_BY="Hazel Fraser" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5815500165104315" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="295" TOTAL_2="287" WEIGHT="100.0" Z="0.5511220453585876">
<NAME>All cause mortality, including sudden deaths</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9533090813520047" CI_START="0.6868521799737264" DF="0.0" EFFECT_SIZE="1.1582895150561887" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.2907709691992554" LOG_CI_START="-0.16313671902387533" LOG_EFFECT_SIZE="0.06381712508768994" MODIFIED="2009-04-08 14:50:05 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.5815500165104315" STUDIES="1" TAU2="0.0" TOTAL_1="295" TOTAL_2="287" WEIGHT="100.0" Z="0.5511220453585876">
<NAME>Oestrogen</NAME>
<DICH_DATA CI_END="1.9533090813520042" CI_START="0.6868521799737264" EFFECT_SIZE="1.1582895150561887" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="29" LOG_CI_END="0.29077096919925527" LOG_CI_START="-0.16313671902387533" LOG_EFFECT_SIZE="0.06381712508768994" ORDER="23" O_E="2.067010309278352" SE="0.26662762294156084" STUDY_ID="STD-VASCA-1966" TOTAL_1="295" TOTAL_2="287" VAR="14.066618797434398" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.4838667496885827" CI_START="0.7170132172866419" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0314805244011556" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="78" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.17139490331954327" LOG_CI_START="-0.14447283855570453" LOG_EFFECT_SIZE="0.013461032381919378" METHOD="PETO" MODIFIED="2009-04-08 14:50:09 +0100" MODIFIED_BY="Hazel Fraser" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8673292848886414" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="295" TOTAL_2="287" WEIGHT="100.0" Z="0.16705180786526416">
<NAME>Serious vascular events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4838667496885827" CI_START="0.7170132172866419" DF="0.0" EFFECT_SIZE="1.0314805244011556" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="78" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.17139490331954327" LOG_CI_START="-0.14447283855570453" LOG_EFFECT_SIZE="0.013461032381919378" MODIFIED="2009-04-08 14:50:09 +0100" MODIFIED_BY="Hazel Fraser" NO="1" P_CHI2="1.0" P_Z="0.8673292848886414" STUDIES="1" TAU2="0.0" TOTAL_1="295" TOTAL_2="287" WEIGHT="100.0" Z="0.16705180786526416">
<NAME>Oestrogen</NAME>
<DICH_DATA CI_END="1.4838667496885827" CI_START="0.7170132172866419" EFFECT_SIZE="1.0314805244011556" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="78" LOG_CI_END="0.17139490331954327" LOG_CI_START="-0.14447283855570453" LOG_EFFECT_SIZE="0.013461032381919378" ORDER="24" O_E="0.9003436426116878" SE="0.18554227514805982" STUDY_ID="STD-VASCA-1966" TOTAL_1="295" TOTAL_2="287" VAR="29.047866813553856" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-09-03 12:41:40 +0100" MODIFIED_BY="Hazel Fraser">
<APPENDIX ID="APP-01" MODIFIED="2008-09-03 12:41:40 +0100" MODIFIED_BY="Hazel Fraser" NO="1">
<TITLE MODIFIED="2008-09-03 12:41:37 +0100" MODIFIED_BY="Hazel Fraser">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-09-03 12:41:40 +0100" MODIFIED_BY="Hazel Fraser">
<P>1 exp Cerebrovascular disorders/<BR/>2 stroke$.tw.<BR/>3 (cerebrovascular$ or cerebral vascular or CVA$).tw.<BR/>4 (cerebral or cerebellar or brain$ or vertebrobasilar).tw.<BR/>5 (infarct$ or isch?emi$ or thrombo$ or emboli$).tw.<BR/>6 4 and 5<BR/>7 (cerebral or intracerebral or intracranial or parenchymal).tw.<BR/>8 (brain or intraventricular or brainstem or cerebellar).tw.<BR/>9 (infratentorial or supratentorial or subarachnoid).tw.<BR/>10 7 or 8 or 9<BR/>11 (haemorrhage or hemorrhage or haematoma or hematoma).tw.<BR/>12 (bleeding or aneurysm).tw.<BR/>13 11 or 12<BR/>14 10 and 13<BR/>15 transient isch?emic attack$.tw.<BR/>16 1 or 2 or 3 or 6 or 14 or 15<BR/>17 exp Hypercholesterolemia/dt [Drug Therapy]<BR/>18 exp Hyperlipidemia/dt [Drug Therapy]<BR/>19 17 or 18<BR/>20 exp Antilipemic agents/<BR/>21 exp Anion exchange resins/<BR/>22 cholestyramine.tw.<BR/>23 colestipol.tw.<BR/>24 20 or 21 or 22 or 23<BR/>25 clofibrate.tw.<BR/>26 bezafibrate.tw.<BR/>27 ciprofibrate.tw.<BR/>28 fenofibrate.tw.<BR/>29 gemfibrozil.tw.<BR/>30 25 or 26 or 27 or 28 or 29<BR/>31 exp Hydroxymethylglutaryl-coa reductase inhibitors/<BR/>32 hmg-coa reductase inhibitor$.tw.<BR/>33 atorvastatin.tw.<BR/>34 fluvastatin.tw.<BR/>35 lovastatin.tw.<BR/>36 pravastatin.tw.<BR/>37 simvastatin.tw.<BR/>38 statin$.tw.<BR/>39 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38<BR/>40 exp Niacin/<BR/>41 nicotinic acid.tw.<BR/>42 acipimox.tw.<BR/>43 40 or 41 or 42<BR/>44 exp Fish oils/<BR/>45 fish oil$.tw.<BR/>46 omega-3 marine triglycerides.tw.<BR/>47 exp Dietary fiber/<BR/>48 soluble fib##.tw.<BR/>49 44 or 45 or 46 or 47 or 48<BR/>50 19 or 24 or 30 or 39 or 43 or 49<BR/>51 16 and 50<BR/>52 limit 51 to human<BR/>53 limit 51 to animal<BR/>54 52 and 53<BR/>55 53 not 54<BR/>56 51 not 55</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>